Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Clinical Phase
NA
Study Classification
INTERVENTIONAL
Study Start Date
2010-10-31
Study Completion Date
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study hypothesis:
Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity and the metabolic profile of women with polycystic ovary syndrome.
Study aims:
To determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) and testosterone (male hormones) in obese women with polycystic ovary syndrome.
Study design:
Obese women with polycystic ovary syndrome, but not recently been on GH treatment, and presently attending Outpatients Clinic will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of women will be randomized to receive either daily low dose GH or placebo injections first for 12 weeks, before exchanging over for another 12 weeks of treatment after a 4-week washout period. Before, during and after treatment, the subjects will be assessed at frequently with blood tests, scans and fat biopsies. During the study, the subjects will be studied 4 times at the Oregon Clinical and Translational Research Institute (OCTRI). At the first, second and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of insulin-like growth factor-I (a hormone stimulated by growth hormone in the body) in fat; whereas blood tests to examine how well insulin works in the body (insulin sensitivity) will be collected at all visits of the study.
Growth hormone (GH), through its generation of free 'bioavailable' insulin-like growth factor (IGF)-I, can improve insulin sensitivity and the metabolic profile of women with polycystic ovary syndrome.
Study aims:
To determine the mechanism of how low dose GH treatment affects the body's sensitivity to insulin actions and whether this low GH dose can affect the body's handling of steroid hormone levels (cortisol clearance) and testosterone (male hormones) in obese women with polycystic ovary syndrome.
Study design:
Obese women with polycystic ovary syndrome, but not recently been on GH treatment, and presently attending Outpatients Clinic will be invited to participate in this study. The subjects will be assessed at the initial visit to ascertain their suitability before further participating in the study. If suitable, an equal number of women will be randomized to receive either daily low dose GH or placebo injections first for 12 weeks, before exchanging over for another 12 weeks of treatment after a 4-week washout period. Before, during and after treatment, the subjects will be assessed at frequently with blood tests, scans and fat biopsies. During the study, the subjects will be studied 4 times at the Oregon Clinical and Translational Research Institute (OCTRI). At the first, second and final visit, testing will include scans to measure the amount of whole body fat and fat in the stomach area, muscle, and liver; blood tests to measure levels of cortisol, and fat tissue (taken from a biopsy) analysis to measure the density of insulin-like growth factor-I (a hormone stimulated by growth hormone in the body) in fat; whereas blood tests to examine how well insulin works in the body (insulin sensitivity) will be collected at all visits of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Meal Composition on Postprandial Testosterone Concentration in Women With Polycystic Ovary Syndrome
NCT00455338
Polycystic Ovary Syndrome
COMPLETED
NA
Metabolic Study of Women With Polycystic Ovary Syndrome and Sleep Apnea
NCT00696111
Polycystic Ovary Syndrome
Obstructive Sleep Apnea
COMPLETED
NA
The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome
NCT02122380
Polycystic Ovary Syndrome
COMPLETED
PHASE4
Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
NCT01360996
Polycystic Ovary Syndrome
COMPLETED
PHASE4
Ovarian Hyperstimulation Syndrome and Cabergoline
NCT01569256
Polycystic Ovarian Syndrome
Ovarian Hyperstimulation Syndrome
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be a double-blinded cross-over study. Thirty subjects will be screened for eligibility initially, and the first 12 eligible subjects will be enrolled. Six subjects will be randomized to receive the low GH dose (0.1 mg/day) treatment and 6 subjects to receive Placebo treatment for 12 weeks, exchanging their treatment for a further 12 weeks after a 4-week washout period. The study drugs will be stored at the Oregon Health and Science University (OHSU) Research Pharmacy and following randomization, the subjects will be taught by our Endocrine Nurses to self-administer the subcutaneous GH and Placebo injections using Nutropin/Placebo vials and insulin syringes into the abdomen at 2200h. Randomization for treatment assignment will be performed by an investigator not directly involved in the patients' recruitment, treatment and follow-up care. The randomization process will be performed by computerized pre-assigned random codes by blocks, stratified by age and examined for possible differences in body mass index. During their in-patient stay at the Oregon Clinical and Translational Research Institute (OCTRI) at OHSU, subjects will only be allowed to eat the food provided to them by the OCTRI.
Initial Screening Assessment (outpatient)
The following assessments will be performed:
* Written informed consent
* Demographics (demographic information including the subject's birth date, and race)
* Physical exam and medical history
* Previous/significant medical history
* Concomitant medication review
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Laboratory findings, e.g. CBC, electrolytes, and fasting glucose levels
* Visit 1, Baseline Assessment for the First Treatment Phase (in-patient)
The following is a description of the assessments that will be performed after consent is obtained:
* Physical exam and medical history
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Urine pregnancy test
* Fasting blood assessments, e.g., hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
* Randomization to GH or Placebo
* Teach GH or Placebo self-administration
* Visit 2, Final Assessment for the First Treatment Phase (Week 12 +/- 1 week) (outpatient)
The following is a description of the assessments that will be performed at the end of the first treatment phase with either GH or Placebo. Subjects will also be monitored for safety with the collection of the following:
* Physical exam and medical history
* Vital signs, e.g. pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g. hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
Washout Period and Crossover After the first treatment phase with GH or Placebo, the subjects will have a 4-week washout period and the treatment will be crossed over for another 12-week treatment phase with either GH or Placebo. During this time, the subjects will be advised to maintain a stable diet and weight.
Visit 3, Baseline Assessment for the Second Treatment Phase (Week 16 +/- 1 week) (as outpatient)
The following is a description of the assessments that will be performed:
* Physical exam and medical history
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g. hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* Treatment exchanged to Placebo or GH
* Visit 4, Final Assessment for the Second Treatment Phase (Week 28 +/- 1 week) (as inpatient)
The following is a description of the assessments that will be performed at the end of the second treatment phase with either GH or Placebo. Subjects will also be monitored for safety with the collection of the following:
* Physical exam and medical history
* Vital signs, e.g. pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g., hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
* Because of the potentially long duration of Visits 1, 2 and 4, the studies can either be divided into two separate admissions upon prior arrangement or can be done all at once with one admission, depending on the subject's wishes and schedule.
Initial Screening Assessment (outpatient)
The following assessments will be performed:
* Written informed consent
* Demographics (demographic information including the subject's birth date, and race)
* Physical exam and medical history
* Previous/significant medical history
* Concomitant medication review
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Laboratory findings, e.g. CBC, electrolytes, and fasting glucose levels
* Visit 1, Baseline Assessment for the First Treatment Phase (in-patient)
The following is a description of the assessments that will be performed after consent is obtained:
* Physical exam and medical history
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Urine pregnancy test
* Fasting blood assessments, e.g., hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
* Randomization to GH or Placebo
* Teach GH or Placebo self-administration
* Visit 2, Final Assessment for the First Treatment Phase (Week 12 +/- 1 week) (outpatient)
The following is a description of the assessments that will be performed at the end of the first treatment phase with either GH or Placebo. Subjects will also be monitored for safety with the collection of the following:
* Physical exam and medical history
* Vital signs, e.g. pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g. hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
Washout Period and Crossover After the first treatment phase with GH or Placebo, the subjects will have a 4-week washout period and the treatment will be crossed over for another 12-week treatment phase with either GH or Placebo. During this time, the subjects will be advised to maintain a stable diet and weight.
Visit 3, Baseline Assessment for the Second Treatment Phase (Week 16 +/- 1 week) (as outpatient)
The following is a description of the assessments that will be performed:
* Physical exam and medical history
* Vital signs, e.g., pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g. hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* Treatment exchanged to Placebo or GH
* Visit 4, Final Assessment for the Second Treatment Phase (Week 28 +/- 1 week) (as inpatient)
The following is a description of the assessments that will be performed at the end of the second treatment phase with either GH or Placebo. Subjects will also be monitored for safety with the collection of the following:
* Physical exam and medical history
* Vital signs, e.g. pulse and blood pressure measurements
* Height and weight
* Waist circumference measurement
* Concomitant medication review
* Adverse event recording
* Urine pregnancy test
* Fasting blood assessments, e.g., hemoglobin, glucose, insulin, C-peptide, serum total and free IGF-I, IGFBP-3, C-reactive protein, adiponectin, ghrelin, non-esterified fatty acids (NEFAs), testosterone, albumin, sex hormone binding globulin and androstenedione
* A 3-hour one-step hyperinsulinemic euglycemic clamp
* MRS and DEXA scans
* Cortisol clearance rate assessments
* Fat biopsy
* Because of the potentially long duration of Visits 1, 2 and 4, the studies can either be divided into two separate admissions upon prior arrangement or can be done all at once with one admission, depending on the subject's wishes and schedule.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Polycystic Ovary Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Growth hormone or Placebo 0.1 mg/day self-administrated once a day.
Group Type
EXPERIMENTAL
Nutropin
Intervention Type
DRUG
Nutropin 0.1 mg/day self-administered once a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutropin
Nutropin 0.1 mg/day self-administered once a day
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Growth hormone, PCOS, insulin sensitivity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ability to provide written informed consent and comply with study assessments for the full duration of the study.
* Age 21 to 45 years
* Body mass index between 30 to 40 kg/m2
* Diagnosis of PCOS with underlying insulin resistance (assessed by HOMA at screening visit) and/or other features that characterizes the metabolic syndrome such as hypertension ( \> 130/85 mmHg), abdominal obesity (waist circumference \> 88 cm), and acanthosis nigricans
* Diagnosis of normal or impaired glucose tolerance (WHO criteria)
* Stable body weight for at least 6 months prior to study entry (body weight deviating +/- 5 kg from previously recorded weight \> 6 months ago)
* Normal thyroid, renal and hepatic function
* Able to self administer daily GH/Placebo injections
* Age 21 to 45 years
* Body mass index between 30 to 40 kg/m2
* Diagnosis of PCOS with underlying insulin resistance (assessed by HOMA at screening visit) and/or other features that characterizes the metabolic syndrome such as hypertension ( \> 130/85 mmHg), abdominal obesity (waist circumference \> 88 cm), and acanthosis nigricans
* Diagnosis of normal or impaired glucose tolerance (WHO criteria)
* Stable body weight for at least 6 months prior to study entry (body weight deviating +/- 5 kg from previously recorded weight \> 6 months ago)
* Normal thyroid, renal and hepatic function
* Able to self administer daily GH/Placebo injections
Exclusion Criteria
* Inability to comply with study requirements
* Body mass index \< 30 kg/m2 and \> 40 kg/m2 (patients with body mass index \> 40 kg/m2 are excluded because they will not fit into the MRS scanner)
* Untreated hypothyroidism or hyperthyroidism
* Anemia from any cause
* Known diabetes mellitus
* Patients with an increased risk of venous thrombosis or previous history of recurrent venous thrombosis
* Patient on any insulin-sensitizers (e.g., Metformin, Rosiglitazone, Pioglitazone) within 30 days of screening assessment
* Patient on any anti-androgens (e.g., Spironolactone, Cyproterone acetate, Flutamide, Finasteride) within 30 days of screening assessment
* Patient with other concurrent illnesses
* Pregnant (positive pregnancy test) prior enrollment in the study or planning to conceive whilst participating in the study
* Emotional/social instability likely to prejudice study completion
* Previous history of known malignancy
* Recurrent or severe unexplained hypoglycemia
* Known or suspected drug/alcohol abuse
* Patient with any metals in the body
* Any other condition/s that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
* Participation in another simultaneous medical investigation or trial
* Body mass index \< 30 kg/m2 and \> 40 kg/m2 (patients with body mass index \> 40 kg/m2 are excluded because they will not fit into the MRS scanner)
* Untreated hypothyroidism or hyperthyroidism
* Anemia from any cause
* Known diabetes mellitus
* Patients with an increased risk of venous thrombosis or previous history of recurrent venous thrombosis
* Patient on any insulin-sensitizers (e.g., Metformin, Rosiglitazone, Pioglitazone) within 30 days of screening assessment
* Patient on any anti-androgens (e.g., Spironolactone, Cyproterone acetate, Flutamide, Finasteride) within 30 days of screening assessment
* Patient with other concurrent illnesses
* Pregnant (positive pregnancy test) prior enrollment in the study or planning to conceive whilst participating in the study
* Emotional/social instability likely to prejudice study completion
* Previous history of known malignancy
* Recurrent or severe unexplained hypoglycemia
* Known or suspected drug/alcohol abuse
* Patient with any metals in the body
* Any other condition/s that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
* Participation in another simultaneous medical investigation or trial
Minimum Eligible Age
21 Years
Maximum Eligible Age
45 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oregon Health and Science University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kevin Yuen
Associate Professor in Endocrinology
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin C. Yuen, MRCP(UK), MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
David M. Cook, MD
Role: PRINCIPAL_INVESTIGATOR
Oregon Health and Science University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oregon Health and Science University
Portland, Oregon, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9. doi: 10.1210/jc.2003-032046.
Reference Type
BACKGROUND
Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab. 1999 Jun;84(6):1897-9. doi: 10.1210/jcem.84.6.5803. No abstract available.
Reference Type
BACKGROUND
de Boer JA, Lambalk CB, Hendriks HH, van Aken C, van der Veen EA, Schoemaker J. Growth hormone secretion is impaired but not related to insulin sensitivity in non-obese patients with polycystic ovary syndrome. Hum Reprod. 2004 Mar;19(3):504-9. doi: 10.1093/humrep/deh122. Epub 2004 Jan 29.
Reference Type
BACKGROUND
Van Dam EW, Roelfsema F, Helmerhorst FH, Frolich M, Meinders AE, Veldhuis JD, Pijl H. Low amplitude and disorderly spontaneous growth hormone release in obese women with or without polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 Sep;87(9):4225-30. doi: 10.1210/jc.2002-012006.
Reference Type
BACKGROUND
Essah PA, Nestler JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril. 2006 Jul;86 Suppl 1:S18-9. doi: 10.1016/j.fertnstert.2006.04.013.
Reference Type
BACKGROUND
Yuen K, Wareham N, Frystyk J, Hennings S, Mitchell J, Fryklund L, Dunger D. Short-term low-dose growth hormone administration in subjects with impaired glucose tolerance and the metabolic syndrome: effects on beta-cell function and post-load glucose tolerance. Eur J Endocrinol. 2004 Jul;151(1):39-45. doi: 10.1530/eje.0.1510039.
Reference Type
BACKGROUND
Yuen KC, Frystyk J, White DK, Twickler TB, Koppeschaar HP, Harris PE, Fryklund L, Murgatroyd PR, Dunger DB. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clin Endocrinol (Oxf). 2005 Oct;63(4):428-36. doi: 10.1111/j.1365-2265.2005.02359.x.
Reference Type
BACKGROUND
Yuen K, Frystyk J, Umpleby M, Fryklund L, Dunger D. Changes in free rather than total insulin-like growth factor-I enhance insulin sensitivity and suppress endogenous peak growth hormone (GH) release following short-term low-dose GH administration in young healthy adults. J Clin Endocrinol Metab. 2004 Aug;89(8):3956-64. doi: 10.1210/jc.2004-0300.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://familydoctor.org/online/famdocen/home/women/reproductive/gynecologic/620.html
Information for women about polycystic ovary syndrome from the American Academy of Family Physicians.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB3711
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
NCT01482286
TERMINATED
PHASE3
Oral Administration of DCI to Women With PCOS
NCT00497653
TERMINATED
PHASE2/PHASE3
Studying the Starvation Effect on Androgen Metabolism in 20 Healthy Young Women and Comparison to Women With PCOS.
NCT03573063
COMPLETED
NA
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
NCT03905603
RECRUITING
EARLY_PHASE1
Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS
NCT03252223
COMPLETED
PHASE4
Weight Loss Intervention in Women With PCOS
NCT03677362
COMPLETED
NA
Role of Insulin Action and Free Fatty Acids in Hyperandrogenism of Women With Polycystic Ovary Syndrome
NCT01019356
COMPLETED
NA
Correlating Improvement in PCOS Symptoms to the Percentage of Body Weight Lost in Females Also Living With Obesity
NCT06325449
NOT_YET_RECRUITING
NA
Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome
NCT06124300
COMPLETED
NA
Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women
NCT01889199
COMPLETED
PHASE2
Compromised Microcirculation in Women With Polycystic Ovary Syndrome
NCT00757185
COMPLETED
EARLY_PHASE1
Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS.
NCT05751252
COMPLETED
EARLY_PHASE1
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation
NCT01421797
UNKNOWN
NA
Dampening the Reproductive Axis With Continuous Kisspeptin
NCT05971849
COMPLETED
PHASE1
Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome
NCT01569425
UNKNOWN
NA
Time Restricted Eating for the Treatment of PCOS
NCT05629858
COMPLETED
NA
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
NCT04327934
TERMINATED
EARLY_PHASE1
Prevalence of Polycystic Ovary Syndrome (PCOS) in Obese Premenopausal Women
NCT01319162
COMPLETED
A Cooking and Eating Study
NCT01079845
TERMINATED
NA
Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)
NCT02145247
COMPLETED
NA
Time Restricted Feeding Model in Women With Polycystic Ovary Syndrome
NCT06807775
NOT_YET_RECRUITING
NA
Androgen Responses to hCG and Ovarian Morphology in PCOS
NCT03489668
UNKNOWN
NA
Time-restricted Feeding for Treating Polycystic Ovary Syndrome (PCOS)
NCT04580433
COMPLETED
NA
Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)
NCT01792362
COMPLETED
PHASE3
Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome
NCT01859663
COMPLETED